Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
      Description

      This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.

      Conditions
      Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerEsophageal AdenocarcinomaEsophageal Squamous Cell CancerSiewert Type 1 GEJ CancerPancreatic Cancer
      Talk to us